Allspring Global Investments Holdings LLC Acquires 14,976 Shares of United Therapeutics Corporation $UTHR

Allspring Global Investments Holdings LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 16.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 104,785 shares of the biotechnology company’s stock after acquiring an additional 14,976 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in United Therapeutics were worth $52,049,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB grew its stake in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in shares of United Therapeutics during the third quarter worth $44,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, True Wealth Design LLC grew its position in shares of United Therapeutics by 738.5% in the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 96 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase 3 TETON‑1 results: Tyvaso met the trial’s key endpoint in idiopathic pulmonary fibrosis (IPF), driving a sharp runup in the stock because success expands Tyvaso’s addressable market beyond pulmonary arterial hypertension. United Therapeutics (UTHR) Is Up 11.5% After Positive IPF Phase 3 Tyvaso Data Met Key Endpoint
• Positive Sentiment: Company press release and institutional coverage reinforced the data readout, giving investors more confidence in a potential FDA filing and commercial upside for Tyvaso in IPF. United Therapeutics reports positive results for lung drug
• Positive Sentiment: Multiple analyst upgrades and price‑target increases (Bank of America, Wells Fargo, HC Wainwright, others) followed the TETON‑1 readout, amplifying buying pressure and pre‑market gaps. Higher targets highlight expected revenue expansion if IPF approval/commercialization succeeds. United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo
• Positive Sentiment: Sell‑side momentum: some firms (e.g., HC Wainwright) moved to Buy and raised targets materially, which supports further upside if clinical and regulatory paths stay on track. HC Wainwright raises UTHR price target to $660
• Neutral Sentiment: Valuation check: analysts and market write‑ups are reassessing UTHR’s valuation after the IPF data — positive clinical news boosts forward revenue expectations but raises near‑term valuation scrutiny. Investors should weigh upside against higher multiples. Assessing United Therapeutics (UTHR) Valuation After Positive Tyvaso Phase 3 IPF Trial Results
• Neutral Sentiment: Options flow and momentum trading: unusually high options activity and gap‑up headlines indicate speculative positioning that can amplify moves and volatility around catalysts (e.g., filings, guidance). United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
• Neutral Sentiment: Sell‑side balance: some firms raised targets but left neutral/equal‑weight ratings, reflecting disagreement on upside vs. execution risk; that keeps upside concentrated in execution and regulatory milestones. Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
• Negative Sentiment: Near‑term caution: some commentary flags valuation and execution risk plus mixed earnings‑estimate revision trends — these could limit further near‑term gains unless management provides clear regulatory/launch guidance. United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?

United Therapeutics Stock Performance

Shares of UTHR stock opened at $570.27 on Thursday. The company has a market capitalization of $24.99 billion, a PE ratio of 20.44, a price-to-earnings-growth ratio of 1.72 and a beta of 0.75. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $607.89. The business’s fifty day moving average is $502.93 and its 200 day moving average is $476.94.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same period in the previous year, the business earned $6.19 earnings per share. The firm’s revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent research reports. HC Wainwright increased their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday. Wells Fargo & Company lifted their target price on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a report on Tuesday. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. UBS Group increased their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $586.00.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 333,820 shares of company stock valued at $165,495,478. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.